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ABSTRACT
The rapid technique of pyrosequencing was used to examine 123 samples (in the form of DNA
extracts and inactivated sputum) of Mycobacterium spp. Of 99 Mycobacterium tuberculosis samples
investigated for single-nucleotide polymorphisms (SNPs), 68% of isoniazid-resistant isolates analysed
had an AGC ﬁ ACC mutation in katG at codon 315, resulting in the Ser ﬁ Thr substitution
associated previously with isoniazid resistance. Of the rifampicin-resistant isolates, 92% showed SNPs
in rpoB at codons 516, 531 or 526. Inactivated sputum samples and DNA extracts could both be
analysed by pyrosequencing, and the method was able to differentiate rapidly between the closely
related species of the M. tuberculosis complex (M. tuberculosis, Mycobacterium bovis, Mycobacterium
africanum, Mycobacterium canetti and Mycobacterium microti), except between M. tuberculosis, M. canetti
and one of two M. africanum strains. This low-cost, high-throughput technique could be used as a
rapid screen for drug resistance and as a replacement for some of the time-consuming tests used
currently for species identification.
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INTRODUCTION
It has been estimated that one-third of the global
population is infected with Mycobacterium tuber-
culosis, with c. 9 million cases of active tubercu-
losis (TB) and > 2 million deaths occurring each
year [1,2]. These numbers are increasing, as is the
number of individuals infected with strains resist-
ant to first-line anti-TB drugs. In the UK, the
current first-line treatment is a 2-month course of
isoniazid, rifampicin and pyrazinamide, often
with the addition of ethambutol, followed by
isoniazid and rifampicin for a further 4–6 months.
Aminoglycosides such as streptomycin and
amikacin, and fluoroquinolones such as ofloxacin
and ciprofloxacin, are used as second-line agents.
Drug resistance in M. tuberculosis occurs fol-
lowing spontaneous mutation in target genes
such as katG, rpoB and inhA [3]. The mechanisms
and the dominant mutations resulting in the drug
resistance profiles have been well-documented
[3–5]. Isoniazid resistance is often associated with
mutation in a gene encoding catalase-peroxidase
(katG), most frequently a Ser315Thr mutation [6].
Rifampicin inhibits transcription by binding to
the RNA polymerase b-subunit, encoded by the
rpoB gene [7], with resistance resulting from
mutations in the rifampicin resistance-determin-
ing region of rpoB, an 81-bp region encoding
amino-acids 507–533. The most common (70%)
mutations are at codons 526 and 531, and
are associated with high levels of resist-
ance (> 100 mg ⁄L). Less frequent mutations,
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particularly in codon 516, are associated with
lower levels of resistance. The fluoroquinolones
were considered to be alternative drugs, as they
prevent transcription and cell division by sup-
pressing DNA supercoiling [8]. DNA gyrase,
encoded by gyrAB, catalyses negative supercoil-
ing of DNA. Mutations in the short quinolone
resistance-determining region and at codon 94 of
gyrA overcome the DNA gyrase-blocking action
of fluoroquinolones [8].
A rapid screening system for these mutations
among isolates of M. tuberculosis is essential. A
sequence-based method, rather than a DNA
migration or a hybridisation approach, is ideal
for the development of a fast, accurate and high-
throughput system, as this will aid in the identi-
fication of alternative mutations in the regions
analysed, as well as those characterised previ-
ously. The present study investigated the possi-
bility of detecting the most common mutations
by pyrosequencing, a short-read (c. 30–50 bp)
sequencing technique based on the quantitative
detection of pyrophosphate released following
nucleotide incorporation into a growing DNA
chain. The technology has also been used previ-
ously for single-nucleotide polymorphism (SNP)
detection [9].
The slow-growing nature of M. tuberculosis
means that several weeks can elapse before the
susceptibility profile of an isolate is known and
appropriately guided anti-TB chemotherapy can
be put in place. Although genotypic testing cannot
wholly replace phenotypic methods for the detec-
tion of antibiotic resistance, as not all mechanisms
of action (and therefore specific mutations) are
known for the different drugs used, a molecular
screen capable of use on primary clinical samples
to detect most mutations associated with resist-
ance could be invaluable. This study therefore
assessed pyrosequencing as a high-throughput,
cost-effective genotypic screen for M. tuberculosis
isoniazid resistance in which common mutations
associated with resistance were detected in spu-
tum samples and early cultures.
Speciation of mycobacteria has been attempted
previously by sequencing all or part of the 16S
rRNA gene [10], but this approach has failed to
delineate this highly conserved genus. Other
regions of the genome that are useful for myco-
bacterial speciation include rpoB [11,12] and gyrB
[13]. Therefore, the present study also assessed
pyrosequencing as a rapid test for identifying
members of the genus Mycobacterium, and spe-
cifically the M. tuberculosis complex (MTBC),
using a composite assay of these three genes.
As public health intervention strategies and
transmission models may also benefit from the
interpretation of data in the context of phyloge-
netically relevant genetic frameworks (geno-
types) based on SNPs [14,15], a pyrosequencing
assay to determine genotype was also developed.
These three composite high-throughput assays,
designed to be used on sputum samples and
cultures in the early stages of growth to deter-
mine resistance profile, species and genotype,
were applied to three groups of M. tuberculosis




In total, 123 samples of mycobacteria were studied, of which 98
were M. tuberculosis nucleic acid extracts.
Group 1 comprised 72 M. tuberculosis DNA extracts from
three northwest London hospitals [16]. Seven (9.7%) of these
extracted isolates were isoniazid-resistant (Table 1). There
were six epidemiologically related groups of isolates (100
and 203; 113 and 128; 129 and 264; 139 and 140; 232, 251,
252 and 253; 1085 and 1086).
Group 2 comprised 20 M. tuberculosis DNA extracts and
seven inactivated sputum samples containing M. tuberculosis
from northeast England (Newcastle) (Table 1). Fourteen of the
extracted isolates were isoniazid- or isoniazid- and rifampicin-
resistant. The sputum samples, containing > 90 bacilli ⁄field,
were inactivated by boiling in 1 M NaOH for 10 min following
dithiothreitol liquefaction (Sputasol; Oxoid, Basingstoke, UK).
Four of these samples yielded isoniazid-resistant M. tubercu-
losis isolates. A further four sputum samples contained
mycobacterial species other than those causing TB, i.e.,
M. avium complex, M. malmoense and M. chelonae, which were
isoniazid-resistant.
Group 3 comprised 24 DNA extracts from 11 different
Mycobacterium spp. (Table 2) obtained from K. Kremer
(National Institute of Public Health and the Environment,
Bilthoven, The Netherlands) [17].
Primer design
Amplification and pyrosequencing primers were designed by
visual comparison and confirmed with the use of on-line
software (http://www.pyrosequencing.com). The sequence of
M. tuberculosis H37Rv, ATCC 27294, was used as an in-silico
template. Pyrosequencing primers were designed to detect
resistance or species-associated SNPs (Fig. 1). Two of the
regions analysed (katG 463 and gyrA 95) were control regions
that were not associated with drug resistance, but were
associated with genotype assignation of M. tuberculosis [14],
namely: CTG ⁄ACC = genotype I; CGG ⁄ACC = genotype II;
and CGG ⁄AGC = genotype III (Table 1).
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The rifampicin resistance detection assay and the rnpB
species identification assay were designed by M. Krabbe
(Pyrosequencing AB, Uppsala, Sweden). The rpoB species
identification assay was designed to generate c. 100-bp
products by means of an alignment of sequences reported by
Lee et al. [11].
The gyrB MTBC species identification assay targeted the
MTBC-associated SNPs identified by Niemann et al. [13] and
Kasai et al. [18], and was designed to distinguish M. tubercu-
losis, M. bovis, M. africanum and M. microti.
PCR
PCR was used to generate products from the rpoB, katG, gyrA,
gyrB and rnpB genes in a final volume of 50 lL with c. 50 ng
of extracted DNA or 1 lL of inactivated sputum, and 25 lL
of PCR Ready Mix (Sigma-Aldrich, Poole, UK) containing
1.5 U of Taq polymerase, 10 mM Tris-HCl, 50 mM KCl,
1.5 mM MgCl2, gelatine 0.001% v ⁄v, 0.2 mM dNTPs and
stabilisers, and 10 pmol each of the forward and reverse
primers (one of which was biotinylated; Fig. 1). PCR involved
Table 1. Strain information for Mycobacterium tuberculosis isolates in groups 1 and 2: resistance profile, single-nucleotide
















104, 124, 125, 126,
129, 131, 138, 142,
145, 149, 154, 157,
200, 208, 209, 212,
234, 241, 264, 267,
280, 282, 284, 285,
286, 982, 1010, 1023,
1026, 1053
WT AGC GAC CAC TCG GAC CTG ACC I
WT profile 2
98, 100, 105, 106,
113, 114, 121, 122,
128, 136, 139, 140,
156, 203, 205, 218,
222, 223, 231, 237,
263, 269, 1002, 1022,
1030, 1054, 1062,
CDC1551
WT AGC GAC CAC TCG GAC CGG ACC II
WT profile 3
127, 229, 276, 1024,
H37Rv
WT AGC GAC CAC TCG GAC CGG AGC III
WT profile 4
226, 1043 WT AGC GAC CAC TCG GAC Weak ACC I ⁄ II
Resistant profile 1
137, 232, 251, 252,
253, 1085, 1086




16, 17 WT AGC GAC CAC TCG GAC CTG ACC I
WT profile 2
12, 13 WT AGC GAC CAC TCG GAC CGG ACC II
WT profile 3
14, 15 WT AGC GAC CAC TCG GAC CGG AGC III
Resistant profiles
1 INH ⁄RIF ACC GAC CAC TTG GAC CTG ACC I
8 INH AGC GAC CAC TCG GAC CTG ACC I
9 INH AGC GAC CAC TCG GAC CGG AGC III
10 INH ⁄RIF ⁄EMB ⁄PZA ACC GCC CAC TCG GAC CTG ACC I
11 INH ⁄RIF ⁄EMB AGC GAC TCC Weak GAC CGG ACC II
22 INH ⁄RIF ⁄EMB ACC GAC CAC TTG GAC CTG ACC I
23 INH ⁄RIF ⁄PZA AGC GAC CAC TTG GAC CGG ACC II
24 INH ⁄RIF ⁄EMB AGC GAC TCC Weak GAC CGG ACC II
25 INH ⁄RIF ACC GAC GAC TCG GAC CGG ACC II
26 INH ⁄RIF ⁄EMB ACC GAC TAC TCG GAC CTG ACC I
27 INH ⁄RIF ⁄EMB ACC GAC GAC TCG GAC CGG ACC II
31 INH ⁄RIF ⁄EMB AGC GAC CAC TCG GAC CGG ACC II
33 INH ⁄RIF ⁄EMB ACC GAC CAC TTG GAC CTG ACC I
35 INH ⁄RIF ACC TAC CAC TCG GAC CTG ACC I
Newcastle isolates
(inactivated sputum)
36 INH AGC GAC CAC TCG ND CTG ND I
37 INH AGC GAC CAC TCG ND CTG ND I
38 INH ACC GAC CAC TCG ND CGG ND II ⁄ III
39 INH ACC GAC CAC TCG ND CTG ND I
40 WT AGC ND ND ND ND CGG ND II ⁄ III
41 WT AGC ND ND ND ND CTG ND I
42 WT AGC GAC CAC TCG ND CGG ND II ⁄ III
WT, wild-type; INH, isoniazid; RIF, rifampicin; EMB, ethambutol; PZA, pyrazinamide; ND not done.
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denaturation at 94C for 2 min, followed by 35 cycles of 94C
for 30 s, 60C for 30 s and 72C for 1 min, followed by a final
extension at 72C for 10 min. Amplification products were
checked on a 96-well Ready-To-Run agarose gel (Amersham
Biosciences, Chalfont St Giles, UK). When PCR performed
directly on sputum samples resulted in low yields, 1 lL of
the initial product was re-amplified to generate sufficient
product for sequencing.
Pyrosequencing
Pyrosequencing was performed with the SQA kit (Pyrosequ-
encing AB) and the pyrosequencing primers shown in Fig. 1.
Briefly, 20 lL of biotinylated PCR product was bound to
streptavidin-coated sepharose beads and denatured. After
washing, the products were transferred to a 96-well microtitre
plate and 20 qmol of pyrosequencing primer was annealed in a
45-lL reaction volume. Once the reaction cartridge was loaded
with dNTPs, enzyme and substrate from the kit, the cart-
ridge and reaction plate were placed in the instrument
(Pyrosequencing AB) for analysis. Depending on the number
of nucleotide additions (each nucleotide addition cycle




The most frequent mutations associated with
isoniazid, rifampicin and fluoroquinolone resist-
ance were detected with the primers described in
Fig. 1. PCR products were generated from all 99
M. tuberculosis samples tested (both extracted
nucleic acid and sputum samples). In group 1, an
AGC ﬁ ACC mutation in katG at codon 315,
resulting in a Ser ﬁ Thr substitution (Fig. 2), was
identified in all of the isoniazid-resistant extracts
(Table 1). Two groups (n = 4; n = 2) of these
samples were related epidemiologically. In group
2, the samemutation was identified in ten of the 18
isoniazid-resistant samples (Table 1). Mutations
associated with resistance at gyrA codon 94 were
not detected, although PCR products and pyrose-
quence data were generated from all samples, and
all replicates gave identical pyrosequence data. In
group 2, the rpoB positions analysed showed
mutations, compared to the wild-type, in 11 of
the 12 extracts of isoniazid- and rifampicin-resist-
ant isolates. Point mutations were identified at
codon 516 in two samples (10 and 35), at codon 526
in five samples (11, 24–27), and at codon 531 in four
samples (1, 22, 23 and 33) (Table 1). No mutations
were identified at gyrA codon 95.
PCR products were not amplified from the four
inactivated sputum samples containing Mycobac-
terium spp. other than those causing TB. How-
ever, in group 2, a katG codon 315 mutation was
identified in two of the four inactivated sputum
samples containing isoniazid-resistant MTBC
(determined by resistance ratio testing [19])
(Table 1).
Genotyping
SNPs at katG codon 463 and gyrA codon 95 are not
associated with resistance, but were used to
Table 2. Identification of Mycobacte-
rium spp. in group 3 on the basis
of single-nucleotide polymorphism


















1 M. tuberculosis (H37Rv) MTBC MTBC C G C G
2 M. bovis BCG MTBC MTBC C A T T
3 M. canettii MTBC MTBC C G C G
4 M. canettii MTBC MTBC C G C G
5 M. africanum MTBC MTBC C G C T
6 M. africanum MTBC MTBC C G C G
7 M. microti MTBC MTBC T G C T
8 M. microti MTBC MTBC T G C T
9 M. bovis MTBC MTBC C A T T
10 M. bovis MTBC MTBC C A T T
11 M. avium M. avium M. avium C G C G
12 M. avium M. avium M. avium C G C G
13 M. kansasii M. kansasii M. kansasii C G C G
14 M. kansasii M. kansasii M. kansasii C G C G
15 M. gordonae Unclear M. gordonae C G C T
16 M. gordonae Unclear M. gordonae C G C T
17 M. smegmatis M. smegmatis M. smegmatis C G C G
18 M. smegmatis M. smegmatis M. smegmatis C G C G
19 M. xenopi M. xenopi M. xenopi C No data C No data
20 M. xenopi M. xenopi M. xenopi C No data C No data
21 M. tuberculosis MTBC MTBC C G C G
22 M. tuberculosis MTBC MTBC C G C G
23 M. tuberculosis MTBC MTBC C G C G
24 M. tuberculosis MTBC MTBC C G C G
MTBC, Mycobacterium tuberculosis complex.
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separate genotypes I–III. The results are shown in
Table 1.
Identification
DNA sequences of all rpoB and rnpB fragments
generated were compared with sequences gener-
ated previously for mycobacteria [11,12]. Both the
rnpB and the rpoB short (25–30 bp) sequence
assays correctly identified all of the mycobacterial
species tested, with the exception of M. gordonae,
which failed to produce a clean sequence with the
rnpB assay (Table 2). As expected, neither of these
assays could separate members of the MTBC.
However, the gyrB SNP assays correctly differen-
tiated between the various species, except
between M. tuberculosis, M. canetti and one of
the two M. africanum strains (Table 2). For the
MTBC only, SNP position 675 was always C
except for M. microti (T), position 756 was always
G except for M. bovis (A), position 1410 was
always C except forM. bovis (T), and position 1450
was always T except for M. tuberculosis, M. canetti
andM. africanum type II (G). A schematic diagram
showing the identification algorithm used is given
in Fig. 3.
Fig. 1. Location of single-nucleotide polymorphisms (SNP) and pyrosequencing primers in PCR amplicons. SNPs of
interest are shown in bold, and pyrosequencing primers are shown in italics. Products generated with a biotinylated
forward primer (i.e., sequenced in the opposite direction) are marked with asterisks.
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DISCUSSION
In the UK, molecular tests for multidrug resist-
ance (MDR) are carried out only following
consideration of epidemiological factors such as
nationality or close contact with an individual
known to be infected with multidrug-resistant TB.
Nationally, < 1% of isolates are multidrug-resis-
tant [20], although isoniazid resistance is more
common (6–10%). Inappropriate prescription of
isoniazid to patients infected with an isoniazid-
resistant strain can cause liver damage and may
drive mutation to MDR by the so-called ‘amplifier
effect’, whereby resistant TB strains gain addi-
tional resistance to further anti-TB drugs. Correct
treatment with first-line drugs usually prevents
development of drug resistance in most patients,
but it aggravates drug resistance in patients
harbouring resistant strains, so that previous
anti-TB treatment is a risk factor for MDR [20].
Antibiotic susceptibility testing is carried out on
isolates from all new TB cases in the UK. The katG
gene is the most commonly targeted region
involved in isoniazid resistance, with mutations
at codon 315 occurring in 30–90% of isoniazid-
resistant isolates, depending on geographical
distribution [7,21–23].
Recently, real-time molecular assays have been
developed to detect mutations associated with
antibiotic resistance in M. tuberculosis. These
include the use of specific hybridisation probes
for use with the LightCycler, a line probe assay
and PCR restriction fragment length polymorph-
ism analysis [24–26]. The real-time PCR methods
are fast, but DNA is extracted from cultured
clinical isolates, which adds to the cost and time
of the assay, and data interpretation can be
subjective. Line probe assays are also carried out
on DNA extracted from cultures, and the assay
can take 1–2 days to complete [25]. PCR restric-
tion fragment length polymorphism analysis
requires DNA extraction, amplification, a 4-h
restriction endonuclease digestion period and
polyacrylamide gel electrophoresis.
In M. tuberculosis samples from the UK, the
AGC ﬁ ACC mutation in katG at codon 315,
resulting in a Ser ﬁ Thr substitution, was detec-
ted by pyrosequencing in 68% of isoniazid-resist-
ant isolates. Among the 12 isoniazid- and
rifampicin-resistant isolates analysed, point muta-
tions at codons 516, 531 or 526 were identified in
11 (92%) cases. Importantly, it was possible to
sequence PCR products amplified from all spu-
tum samples containing M. tuberculosis, although
samples containingMycobacterium spp. other than
those causing TB were not amplified. The latter
finding may be a result of a lower bacterial load or
a reduced specificity of primers. Moreover, the
mutations conferring isoniazid resistance in atyp-
ical mycobacteria are not necessarily related to
those in M. tuberculosis. The ability to use clinical
samples without the need for expensive and time-
consuming DNA extraction procedures would
enable this method to be used more widely than is
possible at present. As the whole assay is
Fig. 2. (A) A pyrogram of the wild type for katG Ser315.
The sequence reads GCGGCATC. (B) A pyrogram of a
mutation conferring isoniazid resistance (AGC ﬁ ACC)
at katG 315. The sequence reads CCGGCATC. (N.B. The
first nucleotide in this codon (A) is the last base in the
pyrosequencing primer).
rpoB ID 
MOTT     MTBC
gyrB ID1         gyrB ID2
   SNP 675         SNP 756     SNP 1410        SNP 1450
C>T G>A       C>T T>G
  =M. microti    = M. bovis   = M. bovis      = M. tuberculosis or
                M. canetti or
  M. africanum type II
Fig. 3. Schematic algorithm for the Mycobacterium tubercu-
losis pyrosequencing identification assay.
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conducted in a high-throughput, 96-well format,
hundreds of isolates could be analysed in < 6 h.
The longest step in the process is the PCR (a step
required in all molecular detection assays de-
scribed so far), while the pyrosequencing techni-
que itself, including the PCR clean-up, takes c.
20 min for 96 samples and costs c. 2.70 euro for
each SNP analysed.
The pyrosequencing method produced clear
and objective sequence data. These assays are
based on short-read sequences, designed to give
control sequence data following or preceding the
SNPs of interest. This objectivity is extremely
useful for applications in medical microbiology,
as the technique does not therefore require the
skilled interpretation of bands or peaks required
with other methods.
In the PCR restriction fragment length poly-
morphism study by Leung et al. [26], it was
observed that a particular SNP position in katG
at codon 463, thought previously to be associated
with isoniazid resistance [27], was found primar-
ily in isolates from the south China region. Of 375
(102 isoniazid-resistant and 273 isoniazid-suscept-
ible) isolates, 317 (85%) had Leu463, compared
with the major wild-type Arg463 associated with
isolates from the western world. This particular
SNP is associated with genotype I, thought to be
evolutionarily old, and was described first by
Sreevatsan et al. [14] and in more detail by
Gutacker et al. [15]. Sreevatsan et al. observed
that clusters of cases were caused by genotypic
groups I and II, but not group III organisms, as
the newly emergent group III organisms were
associated with sporadic cases, suggesting that
the pathogen was evolving towards a state of
reduced transmissibility or virulence. The study
in northwest London [16] also revealed epidem-
iologically related groups of isolates, all of which
were either genotype I or II, supporting the
hypothesis that genotypes I and II were associated
with increased transmissibility or virulence. How-
ever, in a separate study of related infections in
the northeast of England, a genotype III cluster
was identified in four unrelated clusters (data not
shown).
The ability to perform the pyrosequencing
assay on inactivated sputum samples has consid-
erable advantages, including the fact that the
speed of this high-throughput assay means that
genotypic resistance screening of all newly diag-
nosed infections in the UK is achievable. The
advantages of identifying isoniazid resistance
easily and cheaply in a single day, rather than
weeks or months, for the individual patient and in
the wider context of preventing MDR are clear,
and antibiotic resistance screening is recommen-
ded for all new M. tuberculosis infections.
Phenotypic tests are available for the identifi-
cation of Mycobacterium spp., but are time-consu-
ming and may lack discriminatory power [11].
Several molecular tests have been developed,
mostly based on 16S rRNA sequence analysis.
However 16S rRNA sequencing fails to differen-
tiate species belonging to the MTBC. Both of the
short-sequence assays described here, based on
rnpB and rpoB, identified the different Mycobacte-
rium spp. tested, although some sequence data
from the rnpB assay were unreadable, presumably
because of a lack of complementarity of the
primers with genomic DNA from some of the
more diverse species, or possibly because of
sequence-specific looping of the single-stranded
DNA template. The use of single-stranded bind-
ing protein or the addition of NNN (where N is
any base) to the 5¢-end of the non-biotinylated
PCR primer during its synthesis may counteract
this effect.
The SNPs used in this assay to differentiate
members of the MTBC were first identified by
Kasai et al. [18] and described in more detail by
Niemann et al. [13]. These SNPs were able to
differentiate between the members of the MBTC,
except for the three most closely related species,
namelyM. tuberculosis,M. canetti andM. africanum.
The present assay discriminated between one of
the M. africanum isolates and M. tuberculosis. It is
likely that the M. africanum isolate identical (G) to
M. tuberculosis at SNP position 1450 belongs to type
II, whereas the other M. africanum isolate tested
belongs to type I. Niemann et al. [13] were able to
discriminate between the two M. africanum types
by analysing a fifth SNP at gyrB position 1311.
Although the differentiation of M. tuberculosis,
M. canetti andM. africanum type IIwasnot achieved
with pyrosequencing, and therefore remains based
onphenotypic characteristics or the use ofmethods
such as deletion analysis and amplified fragment
length polymorphism analysis [28,29], it is likely
that other SNPs that can be used to separate these
closely related species will be identified. Indeed,
Goh et al. [30] have already published data indica-
ting the use of a particular SNP to differentiate
M. canetti from other members of the MBTC.
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In summary, the present study succeeded in
developing and piloting rapid, high-throughput,
short-sequence and SNP-based assays to speciate
and screen for drug resistance in this important
human pathogen. These low-cost assays can be
used to complement current techniques, and may
be used to replace some of the time-consuming
biochemical tests used currently for identification,
and also as a rapid screen for the detection of drug
resistance in M. tuberculosis infections in the UK.
The ability to obtain sequence data directly from
sputum samples containing M. tuberculosis sug-
gests that the assays described here could indicate
species or drug resistance much more rapidly than
methods used currently, and therefore that they
could have a considerable impact on public health
intervention strategies.
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